{"entity": "researcher", "timestamp": "2026-07-20T00:31:24.538Z", "family": "Simonsson", "given": "Ulrika S H", "initials": "USH", "orcid": "0000-0002-3424-9686", "affiliations": ["Department of Pharmaceutical Biosciences and."], "links": {"self": {"href": "https://publications.scilifelab.se/researcher/653eb745f8e847d0b4bac44bba7dec4d.json"}, "display": {"href": "https://publications.scilifelab.se/researcher/653eb745f8e847d0b4bac44bba7dec4d"}}, "publications": [{"entity": "publication", "iuid": "d9c43fdb45fc4f848240ed45faeee3a3", "links": {"self": {"href": "https://publications.scilifelab.se/publication/d9c43fdb45fc4f848240ed45faeee3a3.json"}, "display": {"href": "https://publications.scilifelab.se/publication/d9c43fdb45fc4f848240ed45faeee3a3"}}, "title": "Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic.", "authors": [{"family": "Mockeliunas", "given": "Laurynas", "initials": "L", "orcid": "0000-0002-7008-4946", "researcher": {"href": "https://publications.scilifelab.se/researcher/a59335eec73d457daca2d454dbfe9db3.json"}}, {"family": "van Wijk", "given": "Rob C", "initials": "RC"}, {"family": "Upton", "given": "Caryn M", "initials": "CM"}, {"family": "Peter", "given": "Jonathan", "initials": "J"}, {"family": "Diacon", "given": "Andreas H", "initials": "AH"}, {"family": "Simonsson", "given": "Ulrika S H", "initials": "USH", "orcid": "0000-0002-3424-9686", "researcher": {"href": "https://publications.scilifelab.se/researcher/653eb745f8e847d0b4bac44bba7dec4d.json"}}], "type": "journal article", "published": "2024-03-19", "journal": {"title": "Vaccines (Basel)", "issn": "2076-393X", "volume": "12", "issue": "3", "issn-l": null}, "abstract": "(1) Background: Some individuals are more susceptible to developing respiratory tract infections (RTIs) or coronavirus disease (COVID-19) than others. The aim of this work was to identify risk factors for symptomatic RTIs including COVID-19 and symptomatic COVID-19 during the coronavirus pandemic by using infection incidence, participant baseline, and regional COVID-19 burden data. (2) Methods: Data from a prospective study of 1000 frontline healthcare workers randomized to Bacillus Calmette-Gu\u00e9rin vaccination or placebo, and followed for one year, was analyzed. Parametric time-to-event analysis was performed to identify the risk factors associated with (a) non-specific symptomatic respiratory tract infections including COVID-19 (RTIs+COVID-19) and (b) symptomatic RTIs confirmed as COVID-19 using a polymerase chain reaction or antigen test (COVID-19). (3) Results: Job description of doctor or nurse (median hazard ratio [HR] 1.541 and 95% confidence interval [CI] 1.299-1.822), the reported COVID-19 burden (median HR 1.361 and 95% CI 1.260-1.469 for 1.4 COVID-19 cases per 10,000 capita), or a BMI > 30 kg/m2 (median HR 1.238 and 95% CI 1.132-1.336 for BMI of 35.4 kg/m2) increased the probability of RTIs+COVID-19, while positive SARS-CoV-2 serology at enrollment (median HR 0.583 and 95% CI 0.449-0.764) had the opposite effect. The reported COVID-19 burden (median HR 2.372 and 95% CI 2.116-2.662 for 1.4 COVID-19 cases per 10,000 capita) and a job description of doctor or nurse (median HR 1.679 and 95% CI 1.253-2.256) increased the probability of developing COVID-19, while smoking (median HR 0.428 and 95% CI 0.284-0.648) and positive SARS-CoV-2 serology at enrollment (median HR 0.076 and 95% CI 0.026-0.212) decreased it. (4) Conclusions: Nurses and doctors with obesity had the highest probability of developing RTIs including COVID-19. Non-smoking nurses and doctors had the highest probability of developing COVID-19 specifically. The reported COVID-19 burden increased the event probability, while positive SARS-CoV-2 IgG serology at enrollment decreased the probability of RTIs including COVID-19, and COVID-19 specifically.", "doi": "10.3390/vaccines12030329", "pmid": "38543963", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [{"db": "pmc", "key": "PMC10974083"}, {"db": "pii", "key": "vaccines12030329"}], "notes": [], "created": "2024-11-25T10:34:02.026Z", "modified": "2025-02-28T14:24:54.815Z"}, {"entity": "publication", "iuid": "9500c75664a34a1c88cb37c1ba8d330a", "links": {"self": {"href": "https://publications.scilifelab.se/publication/9500c75664a34a1c88cb37c1ba8d330a.json"}, "display": {"href": "https://publications.scilifelab.se/publication/9500c75664a34a1c88cb37c1ba8d330a"}}, "title": "Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors.", "authors": [{"family": "Faraj", "given": "Alan", "initials": "A", "orcid": "0009-0009-0165-363X", "researcher": {"href": "https://publications.scilifelab.se/researcher/34964c6116584659903eb1805dc12f67.json"}}, {"family": "Nyberg", "given": "Joakim", "initials": "J", "orcid": "0000-0002-2839-4940", "researcher": {"href": "https://publications.scilifelab.se/researcher/b6a24e7a2f36420083dad4f082f2eac4.json"}}, {"family": "Blouse", "given": "Grant E", "initials": "GE"}, {"family": "Knudsen", "given": "Tom", "initials": "T"}, {"family": "Simonsson", "given": "Ulrika S H", "initials": "USH", "orcid": "0000-0002-3424-9686", "researcher": {"href": "https://publications.scilifelab.se/researcher/653eb745f8e847d0b4bac44bba7dec4d.json"}}], "type": "journal article", "published": "2024-03-00", "journal": {"title": "Clin. Pharmacol. Ther.", "issn": "1532-6535", "volume": "115", "issue": "3", "pages": "498-505", "issn-l": "0009-9236"}, "abstract": "Marzeptacog alfa (MarzAA) is under development for subcutaneous treatment of episodic bleeds in patients with hemophilia A/B and was studied in a phase III trial evaluating MarzAA compared with standard-of-care (SoC) for on-demand use. The work presented here aimed to evaluate MarzAA and SoC treatment of bleeding events on a standardized four-point efficacy scale (poor, fair, good, and excellent). Two continuous-time Markov modeling approaches were explored; a four-state model analyzing all four categories of bleeding improvement and a two-state model analyzing a binarized outcome (treatment failure (poor/fair), and treatment success (good/excellent)). Different covariates impacting improvement of bleeding episodes as well as a putative relationship between MarzAA exposure and improvement of bleeding episodes were evaluated. In the final four-state model, higher baseline diastolic blood pressure and higher age (> 33 years of age) were found to negatively and positively impact improvement of bleeding condition, respectively. Bleeding events occurring in knees and ankles were found to improve faster than bleeding events at other locations. The covariate effects had most impact on early treatment success (\u2264 3 hours) whereas at later timepoints (> 12 hours), treatment success was similar for all patients indicating that these covariates might be clinically relevant for early treatment response. A statistically significant relationship between MarzAA zero-order absorption and improvement of bleedings (P < 0.05) were identified albeit with low precision. No statistically significant difference in treatment response between MarzAA and intravenous SoC was identified, indicating the potential of MarzAA for treatment of episodic bleeding events with a favorable subcutaneous administration route.", "doi": "10.1002/cpt.3172", "pmid": "38173172", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [], "notes": [], "created": "2024-11-25T10:09:46.624Z", "modified": "2025-02-28T14:09:39.021Z"}, {"entity": "publication", "iuid": "65b98d5189d04495861c32b42ad11e50", "links": {"self": {"href": "https://publications.scilifelab.se/publication/65b98d5189d04495861c32b42ad11e50.json"}, "display": {"href": "https://publications.scilifelab.se/publication/65b98d5189d04495861c32b42ad11e50"}}, "title": "Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.", "authors": [{"family": "De Jager", "given": "Veronique", "initials": "V", "orcid": "0000-0001-6389-5575", "researcher": {"href": "https://publications.scilifelab.se/researcher/e773047b1ab54376a335e2571c44d971.json"}}, {"family": "Gupte", "given": "Nikhil", "initials": "N"}, {"family": "Nunes", "given": "Silvia", "initials": "S"}, {"family": "Barnes", "given": "Grace L", "initials": "GL"}, {"family": "van Wijk", "given": "Rob Christiaan", "initials": "RC", "orcid": "0000-0001-7247-1360", "researcher": {"href": "https://publications.scilifelab.se/researcher/ae6d15792b974a20adf6ad6efcb4d6d2.json"}}, {"family": "Mostert", "given": "Joni", "initials": "J"}, {"family": "Dorman", "given": "Susan E", "initials": "SE"}, {"family": "Abulfathi", "given": "Ahmed A", "initials": "AA"}, {"family": "Upton", "given": "Caryn M", "initials": "CM"}, {"family": "Faraj", "given": "Alan", "initials": "A"}, {"family": "Nuermberger", "given": "Eric L", "initials": "EL"}, {"family": "Lamichhane", "given": "Gyanu", "initials": "G"}, {"family": "Svensson", "given": "Elin M", "initials": "EM", "orcid": "0000-0002-0093-6445", "researcher": {"href": "https://publications.scilifelab.se/researcher/f670a6b6bfe147429830547702a56bb6.json"}}, {"family": "Simonsson", "given": "Ulrika S H", "initials": "USH", "orcid": "0000-0002-3424-9686", "researcher": {"href": "https://publications.scilifelab.se/researcher/653eb745f8e847d0b4bac44bba7dec4d.json"}}, {"family": "Diacon", "given": "Andreas H", "initials": "AH"}, {"family": "Dooley", "given": "Kelly E", "initials": "KE", "orcid": "0000-0001-9013-5256", "researcher": {"href": "https://publications.scilifelab.se/researcher/c918050f966e4cfcb761ee822918b894.json"}}], "type": "clinical trial, phase ii", "published": "2022-05-15", "journal": {"title": "Am. J. Respir. Crit. Care Med.", "issn": "1535-4970", "volume": "205", "issue": "10", "pages": "1228-1235", "issn-l": "1073-449X"}, "abstract": "Rationale: Carbapenems are recommended for treatment of drug-resistant tuberculosis. Optimal dosing remains uncertain. Objectives: To evaluate the 14-day bactericidal activity of meropenem, at different doses, with or without rifampin. Methods: Individuals with drug-sensitive pulmonary tuberculosis were randomized to one of four intravenous meropenem-based arms: 2 g every 8 hours (TID) (arm C), 2 g TID plus rifampin at 20 mg/kg once daily (arm D), 1 g TID (arm E), or 3 g once daily (arm F). All participants received amoxicillin/clavulanate with each meropenem dose. Serial overnight sputum samples were collected from baseline and throughout treatment. Median daily fall in colony-forming unit (CFU) counts per milliliter of sputum (solid culture) (EBACFU0-14) and increase in time to positive culture (TTP) in liquid media were estimated with mixed-effects modeling. Serial blood samples were collected for pharmacokinetic analysis on Day 13. Measurements and Main Results: Sixty participants enrolled. Median EBACFU0-14 counts (2.5th-97.5th percentiles) were 0.22 (0.12-0.33), 0.12 (0.057-0.21), 0.059 (0.033-0.097), and 0.053 (0.035-0.081); TTP increased by 0.34 (0.21-0.75), 0.11 (0.052-0.37), 0.094 (0.034-0.23), and 0.12 (0.04-0.41) (log10 h), for arms C-F, respectively. Meropenem pharmacokinetics were not affected by rifampin coadministration. Twelve participants withdrew early, many of whom cited gastrointestinal adverse events. Conclusions: Bactericidal activity was greater with the World Health Organization-recommended total daily dose of 6 g daily than with a lower dose of 3 g daily. This difference was only detectable with solid culture. Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. Clinical trial registered with www.clinicaltrials.gov (NCT03174184).", "doi": "10.1164/rccm.202108-1976OC", "pmid": "35258443", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [{"db": "ClinicalTrials.gov", "key": "NCT03174184"}], "notes": [], "created": "2022-11-09T15:42:25.879Z", "modified": "2024-01-16T13:48:36.515Z"}]}